ASCT Utilization Rates in Mantle Cell Lymphoma: Yazeed Sawalha, MD
The hematologist at Ohio State University Comprehensive Cancer Center–The James discussed utilization rates of autologous stem cell transplant in patients with mantle cell lymphoma.
This content originally appeared on our sister site, Cancer Network.
CancerNetwork® spoke with Yazeed Sawalha, MD, hematologist, Ohio State University Comprehensive Cancer Center–The James, to learn more about his recent study on socioeconomic factors to autologous stem cell transplant (ASCT) in patients with mantle cell lymphoma (MCL). Sawalha discussed utilization rates of ASCT in this population.
Only a small number of patients receive ASCT, which could be attributed to patients with MCL being of an older age with more comorbidities. However, even younger patients under the age of 60 years seldom underwent treatment. This could be attributed to socioeconomic factors, or patient and physician preferences, Sawalha concluded.
TRANSCIPT:
We found that, overall, only a minority of patients with MCL actually underwent autologous stem cell transplant—just 17%. Now, this might not be surprising to a lot of people, because the median age of MCL is usually mid to late 60s, and so many patients would be ineligible for transplant just based on age and having comorbidities. Even when we looked at younger patients—patients younger than the age of 60—less than one-third of them underwent ASCT.
I thought that was an interesting finding. I think socioeconomic factors can influence that possibly. But I think patients' and physicians' preferences probably play an important role here, even though we couldn't specifically address that in our study.
